Despite its strong role in tumour progression, the expression of HER3 reported in CRC ranges from 16 to 89%, making it a more frequently observed marker than HER2 but also exhibiting the same wide variation in expression [103,163,173,203,207,208,209] (Table 6). Here, ERBB3 is linked to neoplasm.